Company intelligence / Profile preview

MuReva Phototherapy

Ownership: Private
Development stage: Other

Overview

Pilot clinical studies in head and neck cancer patients show the intraoral PBM device reduces severity of oral mucositis, preserves salivary flow and swallowing ability, with high treatment completion rates (97%), no device-related adverse events, and high patient satisfaction. A pivotal multi-center randomized controlled trial for FDA submission is ongoing.

Therapeutic areas: Oncology
Modalities: DeviceNon-pharmacological therapy (Photobiomodulation)
Industry: Therapeutic Medical Devices

Partnerships

National Institutes of Health/National Science Foundation SBIR grantsacademic medical centers as clinical sites

Beyond the preview

Go deeper on MuReva Phototherapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MuReva Phototherapy.

Explore the full profile